

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**JW (Cayman) Therapeutics Co. Ltd**

**藥明巨諾（開曼）有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2126)**

**VOLUNTARY ANNOUNCEMENT  
BUSINESS UPDATE  
APPOINTMENTS OF CHIEF SCIENTIFIC OFFICER AND  
SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT**

JW (Cayman) Therapeutics Co. Ltd (the “**Company**” or “**JW Therapeutics**”, together with its subsidiaries, the “**Group**”), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce the appointments of Dr. Shaun Paul Cordoba (“**Dr. Cordoba**”) as chief scientific officer (“**CSO**”) and Mr. Raymond J. Hage, Jr. (“**Mr. Hage**”) as senior vice president (“**SVP**”) of corporate development, respectively, of the Company.

**Dr. Cordoba**

Dr. Cordoba is a highly regarded scientist in driving new innovations in cell immunotherapy technology. He is ranked 3rd in the world as patent holder in relation to chimeric antigen receptor (“**CAR**”) technology with well over 270 patent filings in relation to enhancing CAR activity, shielding CAR-T cells from immunosuppression, and improving CAR safety. Prior to joining JW Therapeutics, Dr. Cordoba served as the executive director of synthetic biology and cell signalling at Autolus Therapeutics plc in the United Kingdom, where he led a group of scientists focused on the development of CARs for both haematological and solid tumors. He obtained a Ph.D. in Immunology from the University of Sydney in Australia and held post-doctoral positions at the University of Oxford, Imperial College London, and University College London, respectively, in the United Kingdom.

Dr. Cordoba will oversee the early-stage research and development, and will provide scientific leadership and strategic guidance to develop a robust cell immunotherapy pipeline for the Company.

## **Mr. Hage**

Mr. Hage has a strong business acumen and rich experience in the biotechnology and pharmaceutical industry. He is a founder of Hapten Sciences, and an advisor to companies and venture funds in the biotechnology and vaccine industry. Prior to joining JW Therapeutics, he served as senior vice president of commercial operations and as chief operating officer of Novavax, Inc., a NASDAQ-listed vaccine company in the United States (NASDAQ: NVAX). During his career, Mr. Hage has led several functions including product development, corporate strategy, commercial operations and corporate development, and held positions with Cephalon, Inc. (a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd.) and Eli Lilly & Co. Mr. Hage obtained a masters degree in business administration from Fisher College of Business of the Ohio State University in the United States.

Mr. Hage will lead corporate strategy development and business partnerships to enhance and build the near and long-term pipeline for the Company.

Dr. Yiping James Li, co-founder, Chairman and Chief Executive Officer of JW Therapeutics, commented: “The additions of Dr. Cordoba and Mr. Hage to our senior leadership team bring a wealth of knowledge, experience, expertise that will be vital to JW Therapeutics during the next stage of growth. We will continue to optimize the technology platform to expand our product pipelines to deliver innovative cell immunotherapy products to patients.”

## About JW Therapeutics

JW Therapeutics is an independent, innovative biotechnology company focusing on the developing, manufacturing and commercializing cell immunotherapy products. Co-founded by Juno Therapeutics Inc. (a Bristol Myers Squibb company) and WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司) (whose H Shares are listed on The Stock Exchange of Hong Kong Limited (SEHK: 2359) and A Shares are listed on the Shanghai Stock Exchange (SSE: 603259)) in 2016, JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The Company has built a top world-class platform for technology and product development in cell immunotherapy, as well as a promising product pipeline covering both hematologic malignancies and solid tumors, to bring hope of cure for Chinese and global patients, and to lead the healthy and standardized development of China's cell immunotherapy industry.

For more information, please visit [www.jwtherapeutics.com](http://www.jwtherapeutics.com).

By order of the Board  
**JW (Cayman) Therapeutics Co. Ltd**  
藥明巨諾（開曼）有限公司\*  
**Yiping James Li**  
Chairman

Shanghai, PRC, January 10, 2022

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yiping James Li as Chairman and executive Director; Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr. Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive Directors, and Mr. Chi Shing Li, Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho as independent non-executive Directors.*

\* For identification purpose only